These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

447 related articles for article (PubMed ID: 26795075)

  • 21. FDA Drug Approval: Elotuzumab in Combination with Lenalidomide and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma.
    Gormley NJ; Ko CW; Deisseroth A; Nie L; Kaminskas E; Kormanik N; Goldberg KB; Farrell AT; Pazdur R
    Clin Cancer Res; 2017 Nov; 23(22):6759-6763. PubMed ID: 28249893
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I safety data of lenalidomide, bortezomib, dexamethasone, and elotuzumab as induction therapy for newly diagnosed symptomatic multiple myeloma: SWOG S1211.
    Usmani SZ; Sexton R; Ailawadhi S; Shah JJ; Valent J; Rosenzweig M; Lipe B; Zonder JA; Fredette S; Durie B; Hoering A; Bartlett B; Orlowski RZ
    Blood Cancer J; 2015 Aug; 5(8):e334. PubMed ID: 26252787
    [No Abstract]   [Full Text] [Related]  

  • 23. Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial.
    Mateos MV; Hernández MT; Giraldo P; de la Rubia J; de Arriba F; Corral LL; Rosiñol L; Paiva B; Palomera L; Bargay J; Oriol A; Prosper F; López J; Arguiñano JM; Quintana N; García JL; Bladé J; Lahuerta JJ; Miguel JS
    Lancet Oncol; 2016 Aug; 17(8):1127-1136. PubMed ID: 27402145
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Frequent occurrence of hypophosphatemia among multiple myeloma patients treated with elotuzumab: a single clinic retrospective study.
    Regidor B; Swift R; Eades B; Emamy-Sadr M; Tarhini F; Spektor TM; Berenson JR
    Ann Hematol; 2021 Apr; 100(4):1079-1085. PubMed ID: 33237342
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of elotuzumab for the treatment of multiple myeloma.
    Gavriatopoulou M; Terpos E; Kastritis E; Dimopoulos MA
    Expert Opin Drug Saf; 2017 Feb; 16(2):237-245. PubMed ID: 28060563
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lenalidomide and dexamethasone in patients with relapsed multiple myeloma and impaired renal function: PrE1003, a PrECOG study.
    Mikhael J; Manola J; Dueck AC; Hayman S; Oettel K; Kanate AS; Lonial S; Rajkumar SV
    Blood Cancer J; 2018 Aug; 8(9):86. PubMed ID: 30190454
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth.
    Dimopoulos MA; Lonial S; White D; Moreau P; Palumbo A; San-Miguel J; Shpilberg O; Anderson K; Grosicki S; Spicka I; Walter-Croneck A; Magen H; Mateos MV; Belch A; Reece D; Beksac M; Bleickardt E; Poulart V; Sheng J; Sy O; Katz J; Singhal A; Richardson P
    Br J Haematol; 2017 Sep; 178(6):896-905. PubMed ID: 28677826
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial.
    Usmani SZ; Schjesvold F; Oriol A; Karlin L; Cavo M; Rifkin RM; Yimer HA; LeBlanc R; Takezako N; McCroskey RD; Lim ABM; Suzuki K; Kosugi H; Grigoriadis G; Avivi I; Facon T; Jagannath S; Lonial S; Ghori RU; Farooqui MZH; Marinello P; San-Miguel J;
    Lancet Haematol; 2019 Sep; 6(9):e448-e458. PubMed ID: 31327689
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of elotuzumab in the treatment of relapsed or refractory multiple myeloma.
    Comeau JM; Kelly K; Jean GW
    Am J Health Syst Pharm; 2018 Jan; 75(2):55-66. PubMed ID: 29317395
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function.
    Dimopoulos M; Alegre A; Stadtmauer EA; Goldschmidt H; Zonder JA; de Castro CM; Masliak Z; Reece D; Olesnyckyj M; Yu Z; Weber DM
    Cancer; 2010 Aug; 116(16):3807-14. PubMed ID: 20564094
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lenalidomide is effective and safe for the treatment of patients with relapsed multiple myeloma and very severe renal impairment.
    João C; Freitas J; Gomes F; Geraldes C; Coelho I; Neves M; Lúcio P; Esteves S; Esteves GV
    Ann Hematol; 2016 May; 95(6):931-6. PubMed ID: 27068406
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Elotuzumab: First Global Approval.
    Markham A
    Drugs; 2016 Mar; 76(3):397-403. PubMed ID: 26809244
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial.
    Yee AJ; Bensinger WI; Supko JG; Voorhees PM; Berdeja JG; Richardson PG; Libby EN; Wallace EE; Birrer NE; Burke JN; Tamang DL; Yang M; Jones SS; Wheeler CA; Markelewicz RJ; Raje NS
    Lancet Oncol; 2016 Nov; 17(11):1569-1578. PubMed ID: 27646843
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma.
    Salwender H; Bertsch U; Weisel K; Duerig J; Kunz C; Benner A; Blau IW; Raab MS; Hillengass J; Hose D; Huhn S; Hundemer M; Andrulis M; Jauch A; Seidel-Glaetzer A; Lindemann HW; Hensel M; Fronhoffs S; Martens U; Hansen T; Wattad M; Graeven U; Munder M; Fenk R; Haenel M; Scheid C; Goldschmidt H
    BMC Cancer; 2019 May; 19(1):504. PubMed ID: 31138244
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oprozomib, pomalidomide, and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma.
    Shah J; Usmani S; Stadtmauer EA; Rifkin RM; Berenson JR; Berdeja JG; Lyons RM; Klippel Z; Chang YL; Niesvizky R
    Clin Lymphoma Myeloma Leuk; 2019 Sep; 19(9):570-578.e1. PubMed ID: 31326409
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An open-label, pharmacokinetic study of lenalidomide and dexamethasone therapy in previously untreated multiple myeloma (MM) patients with various degrees of renal impairment - validation of official dosing guidelines.
    Chen CI; Cao Y; Trudel S; Reece DE; Kukreti V; Tiedemann R; Prica A; Paul H; Le LW; Levina O; Kakar S; Lau A; Chen H; Chen E
    Leuk Lymphoma; 2020 Aug; 61(8):1860-1868. PubMed ID: 32476520
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Clinical Pharmacology of Elotuzumab.
    Passey C; Sheng J; Mora J; Tendolkar A; Robbins M; Dodge R; Roy A; Bello A; Gupta M
    Clin Pharmacokinet; 2018 Mar; 57(3):297-313. PubMed ID: 28779463
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Elotuzumab and dexamethasone for relapsed or refractory multiple myeloma patients: A retrospective study.
    Gross Z; Rahbari A; Wirtschafter E; Spektor TM; Udd KA; Bujarski S; Ghermezi M; Nosrati JD; Vidisheva A; Eades B; Cecchi G; Maluso T; Swift R; Berenson JR
    Eur J Haematol; 2018 Jun; 100(6):621-623. PubMed ID: 29524348
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Successful treatment of patients with multiple myeloma and impaired renal function with lenalidomide: results of 4 German centers.
    Oehrlein K; Langer C; Sturm I; Pönisch W; Hahn-Ast C; Kuhn S; Weisel KC
    Clin Lymphoma Myeloma Leuk; 2012 Jun; 12(3):191-6. PubMed ID: 22341857
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Elotuzumab, pomalidomide, and dexamethasone is a very well tolerated regimen associated with durable remission even in very advanced myeloma: a retrospective study from two academic centers.
    Hose D; Schreder M; Hefner J; Bittrich M; Danhof S; Strifler S; Krauth MT; Schoder R; Gisslinger B; Einsele H; Gisslinger H; Knop S
    J Cancer Res Clin Oncol; 2021 Jan; 147(1):205-212. PubMed ID: 32683487
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.